clinical trial

Biopharma Omeros Corporation (NASDAQ: OMER) released additional data Monday from the company’s OMS721 clinical trial in renal disease.  What Happened Omeros shares were down 42.81 percent at $13.96 at the close monday.  The Phase 2 trial measured protein levels in the...